Skip to content

Clinical study of snake antipruritic pills in the treatment of chronic spontaneous urticaria

Clinical study of snake antipruritic pills in the treatment of chronic spontaneous urticaria

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005651
Enrollment
Unknown
Registered
2022-02-17
Start date
2021-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria

Interventions

The test group:Styriquine hydrochloric acid tablets, 10mg, 1 twice/day, oral, course 7 days, while taking the serpentine itching pills, 2.5g, 3 times/day, oral, course 28 days.
The control group:Styriquine hydrochloric acid tablets, 10mg, 1 twice/day, oral, course 7 days.

Sponsors

guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Meet the criteria for diagnosis of chronic spontaneous urticaria: spontaneous wind mass and/or angioedema onset > 6 weeks (Chinese urticaria diagnosis and treatment guide 2018); 2. Age: 18-65 years old, gender-neutral; The degree of itching is light to medium level: light grade is itchy, not obvious (1 point); The number of wind groups is light and medium: light is the number of wind groups< 20 /24h (1 point); Agree to participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Induced urticaria patients (physical: artificial urticaria (skin scratch), cold-contact urticaria, delayed pressure urticaria, hot-contact urticaria, solar urticaria, vibrating angioedema, choline-energy urticaria; nonphysical: water-source urticaria, contact urticaria); 2. Patients with other diseases that can cause itching; Patients with other life-threatening severe systemic symptoms such as co-infection and throat edema; Combined with serious cardiovascular, liver, kidney and other important organs of internal medicine diseases; 5. Communication barriers, people with mental and mental illness; People who have received glucocorticoids, immunosuppressants, etc. within 3 months; 1 month has used Chinese medicine, acupuncture and other treatment of urticaria; 8. Those who have taken quinoa, pentaphospharide, soap or its preparations within 1 month; Those who have a history of allergies to the active ingredients or preparation aids of the ooselta, or have a history of allergies to other foods or drugs; Patients with pregnancy, lactation or recent birth plans; Need high-altitude operators; 12. Participants in clinical trials of other medical facilities or drugs within 3 months; The researchers did not consider it appropriate for participants.

Design outcomes

Primary

MeasureTime frame
The score of itching degree was improved on 7 days(ISS7)(28 days)));

Countries

China

Contacts

Public ContactHONG YI LI

guangdong Provincial Hospital of Chinese Medicine

lihongyich@126.com13602285656

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026